Colorectal Cancer

Zaltrap (aflibercept) has been granted Priority Review of the Biologics License Application (BLA) by the FDA.

Adding cetuximab to a modified version of the leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) adjuvant regimen did not improve disease-free survival in patients with resected stage 3 wild-type KRAS colon cancer vs. mFOLFOX6 alone, according to a study in the April 4 issue of JAMA.

Radiofrequency ablation can be used to treat colorectal cancer liver metastases and salvage surgical recurrence, with a median overall survival of 40 months.

Potentially curative liver resection can be recommended for patients with colorectal cancer and liver metastases with the reassurance that most aspects of health are recovered by three months after surgery and maintained for at least one year.

Jennerex, Inc. announced on March 20 that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.

Combining cetuximab and erlotinib may be effective against certain types of chemotherapy refractive, metastatic colorectal cancer, according to a recent study published in the Journal of Clinical Oncology by Weickhardt et al.